Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 3/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 4/20 | 0.46 |
| ▸ | TACR1 | P25103 | 4/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12587287 | 1.00 | RORC (0.54) | RORCHDAC1HDAC2PDE4BTACR1 | |
| SCHEMBL12513594 | 1.00 | RORC (0.54) | RORCHDAC1HDAC2PDE4BTACR1 | |
| SCHEMBL30693150 | 1.00 | RORC (0.54) | RORCHDAC1HDAC2PDE4BTACR1 | |
| SCHEMBL12435431 | 1.00 | RORC (0.54) | RORCHDAC1HDAC2PDE4BTACR1 | |
| SCHEMBL1968859 | 1.00 | RORC (0.54) | RORCHDAC1HDAC2PDE4BTACR1 | |
| SCHEMBL1971296 | 1.00 | RORC (0.54) | RORCHDAC1HDAC2PDE4BTACR1 | |
| SCHEMBL19893341 | 0.89 | HDAC1 (0.48) | RORCHDAC1HDAC2PDE4BTACR1 | |
| SCHEMBL12513127 | 0.89 | HDAC1 (0.48) | RORCHDAC1HDAC2PDE4BTACR1 | |
| SCHEMBL12435409 | 0.89 | HDAC1 (0.48) | RORCHDAC1HDAC2PDE4BTACR1 | |
| SCHEMBL12513655 | 0.89 | HDAC1 (0.48) | RORCHDAC1HDAC2PDE4BTACR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10087166-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2018-10-02 | — | — | US | disclosed |
| US-20170129877-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2017-05-11 | — | — | US | disclosed |
| US-9586938-B2 | Cyclic amine azaheterocyclic carboxamides | MERCK PATENT GMBH (DE) | 2017-03-07 | — | — | US | disclosed |
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| EP-2598497-A1 | CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES | Merck Patent GmbH (DE) | 2013-06-05 | — | — | EP | disclosed |
| WO-2012016001-A1 | CYCLIC AMINE AZAHETEROCYCLIC CARBOXAMIDES | MERCK PATENT GMBH (DE) | 2012-02-02 | — | — | WO | disclosed |
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| WO-2010032856-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | 武田薬品工業株式会社 (JP) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | RORC 3261/4885HDAC1 1052/4885HDAC2 1094/4885 |
| US-20130217709-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MKI67, AZI2, PCNA | RORC 1474/4885HDAC1 76/4885HDAC2 132/4885 |
| US-20170129877-A1 | Cyclic Amine Azaheterocyclic Carboxamides | MKI67, AZI2, PCNA | RORC 1474/4885HDAC1 76/4885HDAC2 132/4885 |
| US-10087166-B2 | Cyclic amine azaheterocyclic carboxamides | MKI67, AZI2, PCNA | RORC 1474/4885HDAC1 76/4885HDAC2 132/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.